{"id":647903,"date":"2026-05-17T03:32:22","date_gmt":"2026-05-17T03:32:22","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/647903\/"},"modified":"2026-05-17T03:32:22","modified_gmt":"2026-05-17T03:32:22","slug":"my-top-3-healthcare-stocks-for-may-2026-2","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/647903\/","title":{"rendered":"My Top 3 Healthcare Stocks for May 2026"},"content":{"rendered":"<p>Federal healthcare spending is projected to rise from less than $2 trillion today to more than $3 trillion within a decade, per the Committee for a Responsible Federal Budget. Some reasons for the increase include greater use of GLP-1 drugs for weight loss, increasing cancer diagnoses, costly specialty medicines, increased workforce costs due to shortages, and more people with chronic health problems, such as diabetes.<\/p>\n<p>So it makes sense to look to the healthcare field for promising investments. Here are a few to consider.<\/p>\n<p><img alt=\"A family is outdoors, smiling.\" loading=\"lazy\" width=\"880\" height=\"587\" decoding=\"async\" data-nimg=\"1\" class=\"h-auto max-w-full rounded object-contain\" style=\"color:transparent\"   src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/05\/1778988741_903_.jpeg\"\/><\/p>\n<p class=\"caption\">Image source: Getty Images.<\/p>\n<p>1. Pfizer<\/p>\n<p>Pfizer (<a href=\"https:\/\/www.fool.com\/quote\/nyse\/pfe\/\" class=\"font-bold hover:underline\" rel=\"nofollow noopener\" target=\"_blank\">PFE<\/a> 1.63%) was doing well during the early years of COVID-19 &#8212; but those days are behind it, as demand for its vaccine and Paxlovid treatment has slumped. It has other irons in the fire, though, via its <a href=\"https:\/\/www.fool.com\/investing\/2026\/05\/12\/is-pfizer-a-buy-sell-or-hold-in-2026\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">robust pipeline of drugs in development<\/a>, including some cancer and weight-loss drugs.<\/p>\n<p><img alt=\"Pfizer Stock Quote\" loading=\"lazy\" width=\"64\" height=\"64\" decoding=\"async\" data-nimg=\"1\" class=\"w-full flex-none object-contain\" style=\"color:transparent\"  src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/05\/1778988741_101_.png\"\/><\/p>\n<p>Today&#8217;s Change<\/p>\n<p>(-1.63%) $-0.42<\/p>\n<p>Current Price<\/p>\n<p>$25.33<\/p>\n<p>Key Data Points<\/p>\n<p>Market Cap<\/p>\n<p>$144B<\/p>\n<p>Day&#8217;s Range<\/p>\n<p>$25.24 &#8211; $25.83<\/p>\n<p>52wk Range<\/p>\n<p>$22.64 &#8211; $28.75<\/p>\n<p>Volume<\/p>\n<p>37M<\/p>\n<p>Avg Vol<\/p>\n<p>38M<\/p>\n<p>Gross Margin<\/p>\n<p>65.16%<\/p>\n<p>Dividend Yield<\/p>\n<p>6.79%<\/p>\n<p>Its shares seem attractively valued at recent levels, too, with a forward-looking price-to-earnings (P\/E) ratio of 9.0, a bit below the five-year average of 9.7. Better still, Pfizer&#8217;s dividend was recently yielding 6.5%!<\/p>\n<p>Pfizer <a href=\"https:\/\/www.fool.com\/investing\/2026\/05\/11\/is-this-a-sign-pfizers-aggressive-growth-strategy\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">may not grow briskly<\/a> for a while, but it will pay you well to wait.<\/p>\n<p>2. Intuitive Surgical<\/p>\n<p>It&#8217;s not often that you can buy shares of Intuitive Surgical (<a href=\"https:\/\/www.fool.com\/quote\/nasdaq\/isrg\/\" class=\"font-bold hover:underline\" rel=\"nofollow noopener\" target=\"_blank\">ISRG<\/a> 1.66%) at an attractive price. But it recently sported a forward P\/E of 44, well below its five-year average of 55. (Admittedly, <a href=\"https:\/\/www.fool.com\/investing\/2026\/04\/22\/intuitive-surgical-reports-another-blowout-quarter\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">both those numbers are on the steep side<\/a>.)<\/p>\n<p><img alt=\"Intuitive Surgical Stock Quote\" loading=\"lazy\" width=\"64\" height=\"64\" decoding=\"async\" data-nimg=\"1\" class=\"w-full flex-none object-contain\" style=\"color:transparent\"  src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/05\/1778988742_3_.png\"\/><\/p>\n<p>Today&#8217;s Change<\/p>\n<p>(-1.66%) $-7.10<\/p>\n<p>Current Price<\/p>\n<p>$420.96<\/p>\n<p>Key Data Points<\/p>\n<p>Market Cap<\/p>\n<p>$149B<\/p>\n<p>Day&#8217;s Range<\/p>\n<p>$420.61 &#8211; $431.49<\/p>\n<p>52wk Range<\/p>\n<p>$417.74 &#8211; $603.88<\/p>\n<p>Volume<\/p>\n<p>93K<\/p>\n<p>Avg Vol<\/p>\n<p>1.9M<\/p>\n<p>Gross Margin<\/p>\n<p>66.28%<\/p>\n<p>Its valuation isn&#8217;t the only <a href=\"https:\/\/www.fool.com\/investing\/2026\/05\/11\/intuitive-surgicals-moat-is-getting-stronger-is-th\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">reason to invest in this giant<\/a> in the robotic surgery arena. It&#8217;s also simply a great business. Its robotic surgery systems are pricey, costing $1 million or more, but it gets about 77% of its revenue from instruments, accessories, and servicing. That&#8217;s recurring revenue, on top of continued sales of its machines.<\/p>\n<p>3. Eli Lilly<\/p>\n<p>Eli Lilly (<a href=\"https:\/\/www.fool.com\/quote\/nyse\/lly\/\" class=\"font-bold hover:underline\" rel=\"nofollow noopener\" target=\"_blank\">LLY<\/a> 0.01%) has had a great run lately, thanks to its blockbuster GLP-1 weight-loss drugs such as Mounjaro\/Zepbound. Its stock has averaged annual gains of 39.3% over the past five years!<\/p>\n<p>Year to date, though, shares have been down about 7.7% (as of May 12). This presents an opportunity for investors, with Eli Lilly&#8217;s forward P\/E recently at 29, below the five-year average of 37.<\/p>\n<p><img alt=\"Eli Lilly Stock Quote\" loading=\"lazy\" width=\"64\" height=\"64\" decoding=\"async\" data-nimg=\"1\" class=\"w-full flex-none object-contain\" style=\"color:transparent\"  src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/05\/1778988742_171_.png\"\/><\/p>\n<p>Today&#8217;s Change<\/p>\n<p>(-0.01%) $-0.05<\/p>\n<p>Current Price<\/p>\n<p>$1004.92<\/p>\n<p>Key Data Points<\/p>\n<p>Market Cap<\/p>\n<p>$946B<\/p>\n<p>Day&#8217;s Range<\/p>\n<p>$997.41 &#8211; $1014.38<\/p>\n<p>52wk Range<\/p>\n<p>$623.78 &#8211; $1133.95<\/p>\n<p>Volume<\/p>\n<p>2.8M<\/p>\n<p>Avg Vol<\/p>\n<p>3.1M<\/p>\n<p>Gross Margin<\/p>\n<p>82.83%<\/p>\n<p>Dividend Yield<\/p>\n<p>0.79%<\/p>\n<p>Consider that <a href=\"https:\/\/www.fool.com\/investing\/2026\/05\/04\/3-reasons-its-not-too-late-to-buy-eli-lilly-stock\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">in its first quarter, revenue surged<\/a> 56% year over year to $19.8 billion, while adjusted earnings per share soared 156%. Sales of Mounjaro and Zepbound grew by 125% and 80%, respectively. The company keeps cranking out new drugs, too, such as Foundayo, an oral GLP-1 medicine that bypasses shots.<\/p>\n<p>Eli Lilly&#8217;s stock might look pricey with a recent share price topping $1,000, but a stock&#8217;s price alone doesn&#8217;t mean much. You need to compare it to, say, revenue or earnings, and to crunch other numbers to see whether it seems under- or overvalued. <a href=\"https:\/\/www.fool.com\/investing\/2026\/04\/22\/eli-lilly-stock-cheap-surprise-math-valuation-lly\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">Lilly&#8217;s shares actually seem attractively valued<\/a>.<\/p>\n<p>Any or all these stocks could serve you well. Pfizer is ready to deliver significant income while you wait for greater growth, and Intuitive Surgical and Eli Lilly are already growing briskly. Take a closer look at any <a href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/\" class=\"text-cyan-900 hover:text-cyan-800\" rel=\"nofollow noopener\" target=\"_blank\">solid healthcare stocks<\/a> that intrigue you.<\/p>\n","protected":false},"excerpt":{"rendered":"Federal healthcare spending is projected to rise from less than $2 trillion today to more than $3 trillion&hellip;\n","protected":false},"author":2,"featured_media":647904,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59],"tags":[97,252,253],"class_list":["post-647903","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-health","tag-health-care","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/647903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=647903"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/647903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/647904"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=647903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=647903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=647903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}